Abstract P6-05-17: A study of investigating biologic markers of anti-tumor effects of zoledronic acid and taxane-based chemotherapy for metastatic breast cancer in bone: A prospective, multi-center, non-randomized study (BEAT-ZO) (KCSG BR10-13)

2013 ◽  
Author(s):  
YJ Choi ◽  
JW Bae ◽  
HJ Kim ◽  
SY Kang ◽  
YH Park ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Zoledronic Acid ◽  
Randomized Study ◽  
Metastatic Breast ◽  
Biologic Markers

scholarly journals Dosing related effects of zoledronic acid on bone markers and creatinine clearance in patients with multiple myeloma and metastatic breast cancer

2013 ◽  
Vol 53 (4) ◽  
pp. 547-556 ◽  
Author(s):  
Kent Søe ◽  
Jean-Marie Delaissé ◽  
Erik H. Jakobsen ◽  
Charlotte T. Hansen ◽  
Torben Plesner
Keyword(s):  
Breast Cancer ◽  
Multiple Myeloma ◽  
Metastatic Breast Cancer ◽  
Zoledronic Acid ◽  
Creatinine Clearance ◽  
Bone Markers ◽  
Metastatic Breast

scholarly journals Increased risk of SSEs in bone-only metastatic breast cancer patients treated with zoledronic acid

2017 ◽  
Vol 8 ◽  
pp. 18-22 ◽  
Author(s):  
Masashi Yanae ◽  
Shinichiro Fujimoto ◽  
Kaori Tane ◽  
Maki Tanioka ◽  
Kimiko Fujiwara ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Zoledronic Acid ◽  
Cancer Patients ◽  
Metastatic Breast ◽  
Breast Cancer Patients ◽  
Increased Risk

scholarly journals First-line paclitaxel and cisplatin used sequentially or in combination in metastatic breast cancer: A phase II randomized study

2018 ◽  
Vol 30 (1) ◽  
pp. 13-20 ◽  
Author(s):  
Mostafa M. Elserafi ◽  
Ahmed A. Zeeneldin ◽  
Ibrahim M. Abdelsalam ◽  
Hanan R. Nassar ◽  
Manar M. Moneer ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Phase Ii ◽  
Randomized Study ◽  
Metastatic Breast ◽  
First Line
Sign in / Sign up

Export Citation Format

Share Document